Prestige Biologics Co., Ltd. (KOSDAQ:334970)

Prestige Biologics Revenue

Prestige Biologics had revenue of 2.27B KRW in the quarter ending March 31, 2026, a decrease of -34.80%. This brings the company's revenue in the last twelve months to 18.03B, up 168.64% year-over-year. In the fiscal year ending June 30, 2025, Prestige Biologics had annual revenue of 12.53B with 477.83% growth.

• Revenue (ttm): 18.03B
• Revenue Growth: +168.64%
• P/S Ratio: 8.22
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 148.27B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2025	12.53B	10.36B	477.83%
Jun 30, 2024	2.17B	423.21M	24.24%
Jun 30, 2023	1.75B	1.73B	11,115.88%
Dec 31, 2022	15.57M	-3.21B	-99.52%
Dec 31, 2021	3.23B	-	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 9, 2026

Data Sources Report a data error